SCHWARZ REPORTS RESULTS OF PAIN DRUG TRIAL

Schwarz Pharma has announced that Phase III data of its Lacosamide drug to treat epilepsy showed clinically relevant and statistically significant positive results. The drug was well-tolerated, and the data from the trial confirms the results seen in the company's Phase II Lacosamide program.

The drug has also been shown to be a safe and effective treatment for diabetic neuropathic pain.